These observations suggest that NOX4 inhibition should be used cautiously in patients with advanced cirrhosis, and that the safest therapeutic window for dual NOX1/4 inhibition is likely before the development of late-stage fibrotic remodeling. Here, NOX4 is linked to Cirrhosis.